Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2022
Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases
Jing Li, Jun Jiang, Xun Bao, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 6, 2009
The pharmacologic basis for antibody-auristatin conjugate activity
Stephen C Alley, Xinqun Zhang, Nicole M Okeley, et al.
Bioconjugate Chemistry
|
September 21, 2013
Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation
Nicole M Okeley, Brian E Toki, Xinqun Zhang, et al.
Bioanalysis
|
December 10, 2015
Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates
Russell J Sanderson, Nicole D Nicholas, Cassandra Baker Lee, et al.
Bioanalysis
|
May 7, 2013
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper
Boris Gorovits, Stephen C Alley, Sanela Bilic, et al.
Bioconjugate Chemistry
|
March 5, 2008
Contribution of linker stability to the activities of anticancer immunoconjugates
Stephen C Alley, Dennis R Benjamin, Scott C Jeffrey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2010
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate
Nicole M Okeley, Jamie B Miyamoto, Xinqun Zhang, et al.
Protein Engineering, Design & Selection : PEDS
|
April 29, 2006
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte F McDonagh, Eileen Turcott, Lori Westendorf, et al.
Journal of Clinical Pharmacology
|
June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies
Tae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
Hao Sun, Kristen A Cardinal, Larry Wienkers, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 21, 2022
Mechanistic Modeling of Central Nervous System Pharmacokinetics and Target Engagement of HER2 Tyrosine Kinase Inhibitors to Inform Treatment of Breast Cancer Brain Metastases
Jing Li, Jun Jiang, Xun Bao, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 6, 2009
The pharmacologic basis for antibody-auristatin conjugate activity
Stephen C Alley, Xinqun Zhang, Nicole M Okeley, et al.
Bioconjugate Chemistry
|
September 21, 2013
Metabolic engineering of monoclonal antibody carbohydrates for antibody-drug conjugation
Nicole M Okeley, Brian E Toki, Xinqun Zhang, et al.
Bioanalysis
|
December 10, 2015
Antibody-conjugated drug assay for protease-cleavable antibody-drug conjugates
Russell J Sanderson, Nicole D Nicholas, Cassandra Baker Lee, et al.
Bioanalysis
|
May 7, 2013
Bioanalysis of antibody-drug conjugates: American Association of Pharmaceutical Scientists Antibody-Drug Conjugate Working Group position paper
Boris Gorovits, Stephen C Alley, Sanela Bilic, et al.
Bioconjugate Chemistry
|
March 5, 2008
Contribution of linker stability to the activities of anticancer immunoconjugates
Stephen C Alley, Dennis R Benjamin, Scott C Jeffrey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2010
Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate
Nicole M Okeley, Jamie B Miyamoto, Xinqun Zhang, et al.
Protein Engineering, Design & Selection : PEDS
|
April 29, 2006
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte F McDonagh, Eileen Turcott, Lori Westendorf, et al.
Journal of Clinical Pharmacology
|
June 12, 2013
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies
Tae H Han, Ajay K Gopal, Radhakrishnan Ramchandren, et al.
Cancer Chemotherapy and Pharmacology
|
April 18, 2022
Elimination of tucatinib, a small molecule kinase inhibitor of HER2, is primarily governed by CYP2C8 enantioselective oxidation of gem-dimethyl
Hao Sun, Kristen A Cardinal, Larry Wienkers, et al.
Page
of 4